已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy of MEK inhibition in patients with histiocytic neoplasms

克拉斯 MAPK/ERK通路 曲美替尼 MEK抑制剂 神经母细胞瘤RAS病毒癌基因同源物 组织细胞 组织细胞肉瘤 癌症研究 肿瘤科 医学 激酶 内科学 生物 病理 遗传学 癌症 结直肠癌
作者
Eli L. Diamond,Benjamin Heath Durham,Gary A. Ulaner,Esther N Drill,Justin J. Buthorn,Michelle Ki,Lillian E Bitner,Hanna Cho,Robert J. Young,Jasmine H. Francis,Raajit K. Rampal,Mario E. Lacouture,Lynn A. Brody,Neval Özkaya,Ahmet Doǧan,Neal X. Rosen,Alexia E. Iasonos,Omar Ibrahim Abdel-Wahab,David Michael Hyman
出处
期刊:Nature [Nature Portfolio]
卷期号:567 (7749): 521-524 被引量:437
标识
DOI:10.1038/s41586-019-1012-y
摘要

Histiocytic neoplasms are a heterogeneous group of clonal haematopoietic disorders that are marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway1,2. For the 50% of patients with histiocytosis who have BRAFV600 mutations3–5, RAF inhibition is highly efficacious and has markedly altered the natural history of the disease6,7. However, no standard therapy exists for the remaining 50% of patients who lack BRAFV600 mutations. Although ERK dependence has been hypothesized to be a consistent feature across histiocytic neoplasms, this remains clinically unproven and many of the kinase mutations that are found in patients who lack BRAFV600 mutations have not previously been biologically characterized. Here we show ERK dependency in histiocytoses through a proof-of-concept clinical trial of cobimetinib, an oral inhibitor of MEK1 and MEK2, in patients with histiocytoses. Patients were enrolled regardless of their tumour genotype. In parallel, MAPK alterations that were identified in treated patients were characterized for their ability to activate ERK. In the 18 patients that we treated, the overall response rate was 89% (90% confidence interval of 73–100). Responses were durable, with no acquired resistance to date. At one year, 100% of responses were ongoing and 94% of patients remained progression-free. Cobimetinib treatment was efficacious regardless of genotype, and responses were observed in patients with ARAF, BRAF, RAF1, NRAS, KRAS, MEK1 (also known as MAP2K1) and MEK2 (also known as MAP2K2) mutations. Consistent with the observed responses, the characterization of the mutations that we identified in these patients confirmed that the MAPK-pathway mutations were activating. Collectively, these data demonstrate that histiocytic neoplasms are characterized by a notable dependence on MAPK signalling—and that they are consequently responsive to MEK inhibition. These results extend the benefits of molecularly targeted therapy to the entire spectrum of patients with histiocytosis. A proof-of-concept clinical trial of patients with histiocytoses with MAPK-pathway mutations showed durable responses to treatment with the MEK1 and MEK2 inhibitor cobimetinib, which indicates that histiocytic neoplasms are dependent on MAPK signalling.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhr发布了新的文献求助10
1秒前
闫栋完成签到 ,获得积分10
1秒前
简单十三完成签到,获得积分10
1秒前
紫薇的舔狗完成签到 ,获得积分10
2秒前
1499yqq完成签到 ,获得积分10
2秒前
彼岸完成签到,获得积分10
2秒前
纯情的匕完成签到 ,获得积分10
2秒前
3秒前
李博宇发布了新的文献求助10
4秒前
LH发布了新的文献求助10
4秒前
汉堡包的应助被喂喂喂是谁采纳,获得20
5秒前
平常迎天完成签到,获得积分10
6秒前
wnn完成签到,获得积分10
7秒前
薄荷冷饮完成签到 ,获得积分10
7秒前
刘宇童完成签到 ,获得积分10
7秒前
lyh发布了新的文献求助10
8秒前
shiny完成签到 ,获得积分10
8秒前
勤奋的含蕾完成签到 ,获得积分10
9秒前
法兰VA069完成签到 ,获得积分10
9秒前
李爱国的应助被richardhipower采纳,获得10
10秒前
breeze完成签到,获得积分10
10秒前
11秒前
隐形曼青的应助被昏睡的芒果采纳,获得10
12秒前
cindy完成签到,获得积分10
12秒前
星野的应助被00hello00采纳,获得10
13秒前
SavvyYung完成签到,获得积分10
13秒前
kj完成签到 ,获得积分10
14秒前
伶俐的雁梅完成签到 ,获得积分10
15秒前
16秒前
锦鲤完成签到 ,获得积分10
16秒前
lyh完成签到,获得积分10
17秒前
深情安青的应助被开心香岚采纳,获得10
17秒前
LH完成签到,获得积分10
17秒前
18秒前
123完成签到 ,获得积分10
18秒前
18秒前
wzk完成签到 ,获得积分10
20秒前
虚心完成签到,获得积分10
20秒前
畅快羊青完成签到 ,获得积分10
21秒前
孤标傲世完成签到 ,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189866
求助须知:如何正确求助?哪些是违规求助? 9577019
关于积分的说明 21851254
捐赠科研通 7787798
什么是DOI,文献DOI怎么找? 3435795
关于科研通互助平台的介绍 2559856
邀请新用户注册赠送积分活动 2482699